From the Department of Dermatology, Kaiser Permanente Los Angeles Medical Center.
Dr. Jashin Wu discusses combination therapy with tumor necrosis factor inhibitors for psoriasis. For more information, read Dr. Wu's article from the September 2013 issue, "Combination Therapy With Tumor Necrosis Factor Inhibitors in Psoriasis Treatment."
Psoriasis is a systemic disease that affects approximately 2% of the US population. Traditional treatment modalities include phototherapy, topical...
Experience Diagnosing, Understanding Care, and Treatment With Etanercept (EDUCATE) is a multicenter, phase 4, 24-week, open-label study of the...
Generalized pustular psoriasis is a dramatic potentially life-threatening psoriasis variant and represents a major therapeutic challenge. Tumor...
Palmoplantar psoriasis is a disabling condition characterized by recurrent crops of sterile pustules with associated erythema, fissuring, and...
This article, the first in a 2-part series, reviews the treatment of psoriasis with biologic therapy.
This article, the second in a 2-part series, will review interleukin 10 (IL-10) administration, the T-cell receptor mimic peptide, and CTLA4Ig.
